Acquisition Opportunity Since Agrisera was acquired by Olink Holding AB in May 2020, there is a significant opportunity to offer complementary products and integrated solutions leveraging both companies’ antibody expertise and proteomics capabilities.

Expanding Customer Base Agrisera's extensive library of primary and secondary antibodies provides a solid foundation to target biotech research labs, pharmaceutical companies, and academic institutions seeking reliable antibody sources for their research and development projects.

Growth Potential With a modest revenue range of up to 1 million dollars and recent funding of 1.8 million dollars, Agrisera is positioned for scaled growth; offering innovative antibody solutions or support services could attract new clients and increase market share.

Technology Integration The company's use of digital platforms such as HubSpot and Cloudflare CDN indicates a readiness for enhanced online marketing and e-commerce strategies, opening avenues for targeted marketing campaigns and personalized product offerings.

Collaborative Opportunities Given their experienced scientific team and strong online presence, partnerships with distributors, research institutions, or biotech firms could accelerate sales, expand product reach, and foster joint development initiatives.